Journals / Genel Tıp Dergisi / 2022 / Cilt: 32 - Sayı: 6

Novel Inflammatory Prognostic Markers in Lung Cancer Patients Treated with Definitive Chemoradiotherapy

DEFİNİTİF KEMORADYOTERAPİ İLE TEDAVİ EDİLEN AKCİĞER KANSERİ HASTALARINDA YENİ İNFLAMATUAR PROGNOSTİK BELİRTEÇLER

Pages
646–651
Publication Date
2022-12-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The primary endpoint of this study was; to investigate the effect of radiotherapy dose and neutrophil-lymphocyte ratio (NLR) on overall survival (OS) and progression-free survival (PFS).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Primary lung cancer is the most common cancer worldwide and is an increasingly common problem.
📊
Key Findings & Data:We retrospectively examined 99 patients who were stage III A and stage III B at the time of diagnosis, who did not receive surgical treatment, and who received definitive chemoradiotherapy.
💡
Conclusion & Impact:The primary endpoint of this study was; to investigate the effect of radiotherapy dose and neutrophil-lymphocyte ratio (NLR) on overall survival (OS) and progression-free survival (PFS).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Akciğer Kanseri · Definitif Kemoradyoterapi · Prognostik Belirteçler

Abstract

Primary lung cancer is the most common cancer worldwide and is an increasingly common problem. The primary endpoint of this study was; to investigate the effect of radiotherapy dose and neutrophil-lymphocyte ratio (NLR) on overall survival (OS) and progression-free survival (PFS). We retrospectively examined 99 patients who were stage III A and stage III B at the time of diagnosis, who did not receive surgical treatment, and who received definitive chemoradiotherapy. Data of patients such as sex, age, ECOG status, tumor location, pathological subtype, radiotherapy dose, type of chemotherapy, neutrophil/lymphocyte ratio (NLR), and some biochemical parameters and PFS and OS were included in the study by scanning the patient's files. The radiotherapy cut-off value was accepted as 60 Gray. OS was statistically better in patients who received radiotherapy at doses of 60 Gray and above. When the patients with radiotherapy dose less than 60 Gy and patients with more than 60 Gray were evaluated in two groups, the overall survival was 8,569 ± 1,404 / month and 14,326 ± 1,209 / month, respectively. (p <0.05). When we evaluate the patients based on NLR; It was observed that the overall survival of patients below NLR 4 at the time of diagnosis was statistically significantly better. The overall survival of patients with NLR <4.0 and NLR> 4 was 14.32 ± 1.30 / month and 10.54 ± 1.16 / month, respectively. (p <0.05)

Özet

Primer akciğer kanseri dünya çapında en sık görülen kanserdir ve giderek yaygınlaşan bir sorundur. Bu çalışmanın birincil sonlanım noktası; radyoterapi dozu ve nötrofil-lenfosit oranının (NLR) genel sağ kalım (OS) ve progresyonsuz sağ kalım (PFS) üzerindeki etkisini araştırmaktır. Tanı anında evre III A ve evre III B olan, cerrahi tedavi olmayan ve definitif kemoradyoterapi alan 99 hastayı retrospektif olarak inceledik. Hastalara ait cinsiyet, yaş, ECOG durumu, tümör yerleşimi, patolojik alt tip, radyoterapi dozu, kemoterapi tipi, nötrofil/lenfosit oranı (NLR), bazı biyokimyasal parametreler ve PFS ve OS gibi veriler hastaların detaylı dosya taraması yapılarak çalışmaya dahil edildi. Radyoterapi cut-off değeri 60 Gray olarak kabul edildi. OS, 60 Gray ve üzeri dozlarda radyoterapi alan hastalarda istatistiksel anlamlı olacak şekilde daha iyiydi. Radyoterapi dozu 60 Gy'nin altında olan hastalar ve 60 Gray'in üzerinde olan hastalar iki grupta değerlendirildiğinde genel sağ kalım sırasıyla 8.569 ± 1.404 / ay ve 14.326 ± 1.209 / ay idi. (p <0.05). Hastaları NLR'ye göre değerlendirdiğimizde; tanı anında NLR 4'ün altındaki hastaların genel sağ kalımının istatistiksel olarak anlamlı derecede daha iyi olduğu gözlendi. NLO <4.0 ve NLO> 4 olan hastaların genel sağ kalımları sırasıyla 14.32 ± 1.30/ay ve 10.54 ± 1.16/ay idi. (p <0.05)

🔖

Cite This Article

YENİÇERİ, A., GULMEZ, A., HARPUTLUOGLU, H. (2022). Novel Inflammatory Prognostic Markers in Lung Cancer Patients Treated with Definitive Chemoradiotherapy. Genel Tıp Dergisi, Cilt: 32 - Sayı: 6, 646–651. https://ajindex.com/articles/879098

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr An Int Rev J. 2016;7:418–9
  2. Bunn PA. Worldwide overview of the current status of lung cancer diagnosis and treatment. In: Archives of Pathology and Laboratory Medicine. 2012. p. 1478–81
  3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424
  4. Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. Semin Intervent Radiol. 2013;30:93–8
  5. Spiro SG, Porter JC. Lung cancer--where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med. 2002;166:1166–96
  6. Alberg AJ. Cancer: Epidemiology of Lung Cancer. Encycl Hum Nutr. 2012;1–4:259–64
  7. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32:605–44
  8. Inamura K. Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification. Front Oncol. 2017;7:193
  9. Travis WD. Pathology of Lung Cancer. Clin Chest Med. 2011;32:669–92
  10. Masel EK, Berghoff AS, Füreder LM, Heicappell P, Schlieter F, Widhalm G, Gatterbauer B, Dieckmann U, Birner P, Bartsch R, Schur S, Watzke HH, Zielinski CC, Preusser M. Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients. Eur J Cancer Care (Engl). 2017;26:e12707
  11. Zhu Q-Q, Wang C, Chen Y-Y, Ding Z-Y. Impaired Liver Function Implied Shorter Progression Free Survival for EGFR Tyrosine Kinase Inhibitors. Asian Pac J Cancer Prev. 2018;19:2177–81
  12. Arrieta O, Saavedra-Perez D, Kuri R, Aviles-Salas A, Martinez L, Mendoza-Posada D, Castillo P, Astorga A, Guzman E, De la Garza J. Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer. 2009;9:119
  13. Tomita M, Shimizu T, Hara M, Ayabe T, Onitsuka T. Preoperative leukocytosis, anemia and thrombocytosis are associated with poor survival in non-small cell lung cancer. Anticancer Res. 2009;29:2687–90
  14. Urvay SE, Yucel B, Erdis E, Turan N. Prognostic Factors in Stage III Non-Small-Cell Lung CancerPatients. Asian Pac J Cancer Prev. 2016;17:4693–7
  15. Kwas H, Guermazi E, Khatta